glp-1 addiction trials Agonists: Expanding Horizons in Treatment IUPHAR review – Glucagon-like peptide-1

Safety Considerations and Medical Eligibility for Prescription Options Behavioral programs (Weightwatchers) carry minimal medical risk and suit nearly all adults

Surprisingly, restoration of the nucleus tractus solitarius GLP1 neuron projections to the paraventricular hypothalamic nucleus by expression of leptin receptors in nucleus tractus solitarius GLP1 neurons failed to normalize the physiological outcomes of impaired nucleus tractus solitarius GLP1 projections to the paraventricular hypothalamic nucleus (Biddinger et al., 2020)

Glucagon suppression under GLP-1RA therapy: hidden trade-offs for muscle and resilience

Figura 3 Media de la tasa de secrecin de insulina frente a la concentracin de glucosa en pacientes con diabetes tipo 2 durante la infusin de glucosa gradual antes (inicial) y despus de 12 semanas de tratamiento con semaglutida o con placebo y en sujetos sanos no tratados

Study Population : 2,539 adults without diabetes Average age: 44.9 years Average baseline BMI: 38.0 Average baseline weight: 231.1 pounds 67.5% female 70.1% White, 22.3% Hispanic/Latino, 5.4% Black, 2.2% Other Interventions : Tirzepatide 5 mg once weekly (n=630) Tirzepatide 10 mg once weekly (n=636) Tirzepatide 15 mg once weekly (n=630) Placebo once weekly (n=643) All groups: Counseling for 500-calorie deficit and 150 minutes/week physical activity Duration : 72 weeks Primary Outcome - Mean Percentage Weight Loss : Tirzepatide 5 mg: -15.0% (95% CI: -15.9 to -14.2) Tirzepatide 10 mg: -19.5% (95% CI: -20.4 to -18.5) Tirzepatide 15 mg: -20.9% (95% CI: -21.8 to -19.9) Placebo: -3.1% (95% CI: -4.3 to -1.9) Secondary Outcomes - Categorical Weight Loss (15 mg dose): 5% weight loss : 96.0% tirzepatide vs 34.3% placebo 10% weight loss : 89.4% tirzepatide vs 16.6% placebo 15% weight loss : 78.9% tirzepatide vs 8.2% placebo 20% weight loss : 62.7% tirzepatide vs 1.3% placebo 25% weight loss : 42.4% tirzepatide vs 0.3% placebo Trial Completion Rates : Tirzepatide 5 mg: 84.8% Tirzepatide 10 mg: 85.2% Tirzepatide 15 mg: 83.7% Placebo: 91.4% Safety Data (15 mg dose): Gastrointestinal adverse events: 81.0% tirzepatide vs 63.8% placebo Serious adverse events: 6.2% tirzepatide vs 4.2% placebo Discontinuation due to adverse events: 6.2% tirzepatide vs 2.2% placebo Real-World Evidence: Beyond Clinical Trials While randomized controlled trials provide the highest quality efficacy and safety data, real-world evidence studies examine outcomes in routine clinical practice settings without strict trial protocols

It is still unclear whether microbiome changes drive metabolic improvements or simply reflect them